Neil F. McFarlane
CIK 1681098 · President and CEO · last filed 2026-02-10
Neil F. McFarlane is a President and CEO who has filed 26 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for ZVRA, was dated Feb 10, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.79M
4
26
-$2.47M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | President and CEO | 401,850 | $12.65 | $5.08M | -$1.92M | 8 | 2026-02-10 |
| COLL | Director | 49,365 | $34.64 | $1.71M | $0 | 4 | 2024-05-16 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Executive Officer | 0 | $8.22 | $0 | $0 | 4 | 2021-11-24 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Operating Officer | 27,972 | — | — | -$552.6K | 10 | 2019-05-16 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-10 | ZVRA | Mixed | +22,875 | -$125.2K | EDGAR |
| 2026-02-02 | ZVRA | Mixed | +142,334 | -$853.4K | EDGAR |
| 2025-10-10 | ZVRA | Mixed | +30,500 | -$210.9K | EDGAR |
| 2025-02-14 | ZVRA | Sell (S) | −91,817 | -$727.4K | EDGAR |
| 2025-02-10 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2025-02-03 | ZVRA | Exer (M) | +233,333 | $0 | EDGAR |
| 2024-05-16 | COLL | Grant (A) | +7,693 | $0 | EDGAR |
| 2024-02-02 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2023-10-11 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | COLL | Grant (A) | +9,792 | $0 | EDGAR |